VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining PARP inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizzaro, Francesca, Fuso Nerini, Ilaria, Taylor, Molly A., Anastasia, Alessia, Russo, Massimo, Damia, Giovanna, Guffanti, Federica, Guana, Francesca, Ostano, Paola, Minoli, Lucia, Hattersley, Maureen M., Arnold, Stephanie, Ramos-Montoya, Antonio, Williamson, Stuart C., Galbiati, Alessandro, Urosevic, Jelena, Leo, Elisabetta, Cavallaro, Ugo, Ghilardi, Carmen, Barry, Simon T., Bani, Maria Rosa, Giavazzi, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572452/
https://www.ncbi.nlm.nih.gov/pubmed/34742344
http://dx.doi.org/10.1186/s13045-021-01196-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572452/
https://www.ncbi.nlm.nih.gov/pubmed/34742344
http://dx.doi.org/10.1186/s13045-021-01196-x

Ejemplares similares